Clin Colon Rectal Surg 2024; 37(03): 180-184
DOI: 10.1055/s-0043-1770730
Review Article

Management of Rectal Cancer in Lynch Syndrome: Balancing Risk Reduction and Quality of Life

Bradley A. Krasnick
1   Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio
Matthew F. Kalady
1   Division of Colorectal Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio
› Author Affiliations


Patients with Lynch syndrome are predisposed to developing colorectal cancer and a variety of extracolonic malignancies, at a young age. The management of rectal cancer in the setting of Lynch syndrome is a complex clinical scenario that requires the expertise of a multidisciplinary management team. In this review, we delve into the approach for rectal cancer in these patients, and specifically focus on several key aspects of treatment. Some unique aspects of rectal cancer in Lynch syndrome include the decision between proctectomy alone versus total proctocolectomy with or without an ileal pouch, the utility of chemotherapy and immunotherapy, nonoperative rectal cancer management, and the management of rectal polyps. Throughout, we highlight the delicate interplay between future cancer risk reduction and quality of life optimization.

Publication History

Article published online:
10 August 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

  • References

  • 1 Cunningham LA, Gasior A, Kalady MF. Management of colorectal cancer in hereditary syndromes. Surg Oncol Clin N Am 2022; 31 (02) 307-319
  • 2 Pearlman R, Frankel WL, Swanson B. et al; Ohio Colorectal Cancer Prevention Initiative Study Group. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 2017; 3 (04) 464-471
  • 3 Möslein G, Nelson H, Thibodeau S, Dozois RR. Rectal carcinomas in HNPCC [in German]. Langenbecks Arch Chir Suppl Kongressbd 1998; 115: 1467-1469
  • 4 Lee JS, Petrelli NJ, Rodriguez-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer. Am J Surg 2001; 181 (03) 207-210
  • 5 Cirillo L, Urso ED, Parrinello G. et al. High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. Ann Surg 2013; 257 (05) 900-904
  • 6 Karagkounis G, Stocchi L, Lavery IC. et al. Multidisciplinary conference and clinical management of rectal cancer. J Am Coll Surg 2018; 226 (05) 874-880
  • 7 Herzig DO, Buie WD, Weiser MR. et al. Clinical practice guidelines for the surgical treatment of patients with lynch syndrome. Dis Colon Rectum 2017; 60 (02) 137-143
  • 8 Win AK, Parry S, Parry B. et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Ann Surg Oncol 2013; 20 (06) 1829-1836
  • 9 Kalady MF, Lipman J, McGannon E, Church JM. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. Ann Surg 2012; 255 (06) 1121-1125
  • 10 Fazio VW, Kiran RP, Remzi FH. et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg 2013; 257 (04) 679-685
  • 11 Liska D, Kalady MF. Colorectal surgery in lynch syndrome patients: when and how?. Curr Colorectal Cancer Rep 2015; 11 (02) 45-53
  • 12 Pemberton JH, Phillips SF, Ready RR, Zinsmeister AR, Beahrs OH. Quality of life after Brooke ileostomy and ileal pouch-anal anastomosis. Comparison of performance status. Ann Surg 1989; 209 (05) 620-626 , discussion 626–628
  • 13 Kirat HT, Remzi FH, Kiran RP, Fazio VW. Comparison of outcomes after hand-sewn versus stapled ileal pouch-anal anastomosis in 3,109 patients. Surgery 2009; 146 (04) 723-729 , discussion 729–730
  • 14 Benoist S, Panis Y, Boleslawski E, Hautefeuille P, Valleur P. Functional outcome after coloanal versus low colorectal anastomosis for rectal carcinoma. J Am Coll Surg 1997; 185 (02) 114-119
  • 15 Hassan I, Larson DW, Cima RR. et al. Long-term functional and quality of life outcomes after coloanal anastomosis for distal rectal cancer. Dis Colon Rectum 2006; 49 (09) 1266-1274
  • 16 Keane C, Fearnhead NS, Bordeianou LG. et al; LARS International Collaborative Group. International consensus definition of low anterior resection syndrome. Dis Colon Rectum 2020; 63 (03) 274-284
  • 17 Keane CR, O'Grady G, Bissett IP. et al. Functional outcome of laparoscopic-assisted resection versus open resection of rectal cancer: a secondary analysis of the Australasian Laparoscopic Cancer of the Rectum trial. Dis Colon Rectum 2022; 65 (07) e698-e706
  • 18 Kang SB, Cho JR, Jeong SY. et al; Seoul Colorectal Research Group (SECOG). Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): a long-term prospective, multicentre, cohort study. Lancet Reg Health West Pac 2020; 6: 100087
  • 19 Murphy PB, Khot Z, Vogt KN, Ott M, Dubois L. Quality of life after total proctocolectomy with ileostomy or IPAA: a systematic review. Dis Colon Rectum 2015; 58 (09) 899-908
  • 20 Benson AB, Vebook AP. et al. NCCN clinical practice guidelines in oncology: Rectal cancer. Updated 2022. Accessed December 2, 2022 at:
  • 21 You YN, Hardiman KM, Bafford A, Al-Hawary MM. et al; On Behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. Dis Colon Rectum 2020; 63 (09) 1191-1222
  • 22 Battersby NJ, How P, Moran B. et al; MERCURY II Study Group. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 2016; 263 (04) 751-760
  • 23 Hasan S, Renz P, Wegner RE. et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a national cancer database (NCDB) analysis. Ann Surg 2020; 271 (04) 716-723
  • 24 Cercek A, Dos Santos Fernandes G, Roxburgh CS. et al. mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res 2020; 26 (13) 3271-3279
  • 25 Ni K, Zhan Y, Liu Z. et al. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients. J Surg Oncol 2022; 125 (04) 692-702
  • 26 André T, Shiu KK, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383 (23) 2207-2218
  • 27 Cercek A, Lumish M, Sinopoli J. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022; 386 (25) 2363-2376
  • 28 Fernandez LM, São Julião GP, Figueiredo NL. et al; International Watch & Wait Database Consortium. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol 2021; 22 (01) 43-50
  • 29 Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum 2017; 60 (03) 335-345
  • 30 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
  • 31 Gorgun E, Benlice C, Church JM. Does cancer risk in colonic polyps unsuitable for polypectomy support the need for advanced endoscopic resections?. J Am Coll Surg 2016; 223 (03) 478-484
  • 32 Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372 (26) 2509-2520